ImmunoGen, Inc.
IMGN
株式のランク
#2920
ImmunoGen, Inc. is a clinical-stage biotechnology enterprise that specializes... ImmunoGen, Inc. is a clinical-stage biotechnology enterprise that specializes in the creation of antibody-drug conjugate (ADC) therapies for cancer treatment. A prominent drug in their pipeline is mirvetuximab soravtansine, an ADC designed to target folate-receptor alpha (FRa), which is currently undergoing Phase III clinical trials for patients with platinum-resistant ovarian cancer. Another significant candidate, Pivekimab sunirine, a CD123-targeting ADC, is progressing through Phase II studies for acute myeloid leukemia and blastic plasmacytoid dendritic cell neoplasm. Beyond its clinical efforts, the company's preclinical portfolio includes IMGC936, an ADC being co-developed with MacroGenics, Inc., and IMGN151, another anti-FRa therapeutic. ImmunoGen maintains strategic collaborations with a range of key industry players, such as Roche, Amgen/Oxford BioTherapeutics, Bayer HealthCare AG, Eli Lilly and Company, Novartis Institutes for BioMedical Research, Inc., CytomX Therapeutics, Inc., Fusion Pharmaceuticals Inc., Debiopharm International SA, and MacroGenics, Inc. Founded in 1980, ImmunoGen, Inc. is headquartered in Waltham, Massachusetts.
株価
$31.23
最終同期: 2024-02-13
時価総額
$6.24B
変化（1日）
0.00%
変化（1年）
-0.03%
国
US
取引 ImmunoGen, Inc. (IMGN)
カテゴリー
Healthcare
ImmunoGen, Inc.（IMGN）の株価履歴
終値の最高値: $29.96 （2024-02-01）
終値の最安値: $3.94 （2023-02-01）
終値の最安値: $3.94 （2023-02-01）
ImmunoGen, Inc. の株価履歴（2023 ～ 2026）
年間株価パフォーマンス
| 年 | パフォーマンス |
|---|---|
| 2024 | 1.66% |
| 2023 | 0.00% |
類似企業または競合の株価
| 企業 | 株価 | 変化率 1年% | 国 |
|---|---|---|---|
| $527.18 | 23.62% |
US
|
|
| $251.29 | 835.90% |
US
|
|
| $137.83 | -3.78% |
AU
|
|
| $890.85 | 9.42% |
NL
|
|
| $766.95 | 9.01% |
CH
|
